Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TT4BT06)

• DTT Name: Integrin alpha-4 (ITGA4) DTT Info
• Gene Name: ITGA4

Molecule-Related Drug & Molecule List

3 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Antegren	DMNC64R	Multiple sclerosis	8A40	Approved	[1]
Natalizumab	DMAK85L	Crohn disease	DD70	Approved	[2]
Vedolizmab	DMV3YMX	Crohn disease	DD70	Approved	[3]

8 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PB006	DMVHGLA	Crohn disease	DD70	Phase 3	[4]
AMG-181	DMODJTX	Crohn disease	DD70	Phase 2	[5]
BIO-1211	DMKICA3	Asthma	CA23	Phase 2	[6]
GSK683699	DMTW79H	Inflammatory bowel disease	DD72	Phase 2	[7]
Senktide	DMOH8LD	Epilepsy	8A60-8A68	Phase 2	[8]
ELND-002	DMM9S51	Autoimmune diabetes	5A10	Phase 1	[9]
ELND-004	DMLQYVD	Autoimmune diabetes	5A10	Phase 1	[9]
PTG-100	DMQNRGE	Ulcerative colitis	DD71	Phase 1	[5]

2 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ASP-2002	DM3XCM1	Ulcerative colitis	DD71	Investigative	[10]
CT301	DMUVQFW	Discovery agent	N.A.	Investigative	[11]

References

• [1] Very late antigen 4 (VLA4) antagonists as anti-inflammatory agents. Curr Opin Chem Biol. 1998 Aug;2(4):453-7.
• [2] Natalizumab in Multiple Sclerosis Treatment: From Biological Effects to Immune Monitoring. Front Immunol. 2020 Sep 24;11:549842.
• [3] Clinical pipeline report, company report or official report of Takeda (2009).
• [4] Efficacy and Safety of Proposed Biosimilar Natalizumab (PB006) in Patients With Relapsing-Remitting Multiple Sclerosis: The Antelope Phase 3 Randomized Clinical Trial. JAMA Neurol. 2023 Mar 1;80(3):298-307.
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] A small-molecule, tight-binding inhibitor of the integrin alpha(4)beta(1) blocks antigen-induced airway responses and inflammation in experimental asthma in sheep. Am J Respir Crit Care Med. 2000 Aug;162(2 Pt 1):603-11.
• [7] Emerging drugs to treat Crohn's disease. Expert Opin Emerg Drugs. 2007 Mar;12(1):49-59.
• [8] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [9] Paxillin binding to the alpha 4 integrin subunit stimulates LFA-1 (integrin alpha L beta 2)-dependent T cell migration by augmenting the activation of focal adhesion kinase/proline-rich tyrosine kinase-2. J Immunol. 2003 Jun 15;170(12):5912-8.
• [10] Asphelia to Present at C21 BioVentures Conference in Napa, CA. 10th Annual C21 BioVentures. May 15, 2008.
• [11] Prolonged reversal of chronic experimental allergic encephalomyelitis using a small molecule inhibitor of alpha4 integrin. J Neuroimmunol. 2002 Oct;131(1-2):147-59.